# Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma

> **NCT07753642** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 47 (estimated)

## Conditions studied

- Nodal T-follicular Helper Cell Lymphoma

## Interventions

- **DRUG:** Golidocitinib
- **DRUG:** Doxorubicin
- **DRUG:** Epirubicin

## Key facts

- **NCT ID:** NCT07753642
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2028-08-31
- **Final completion:** 2029-08-30
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07753642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07753642, "Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07753642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*